Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573600 | 0.86 | RAB9A (0.58) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL31358086 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1573954 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1573855 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1573857 | 0.81 | RAB9A (0.44) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1573607 | 0.77 | TP53 (0.48) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1573602 | 0.74 | KDM4E (0.51) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1574083 | 0.73 | GABRA1 (0.48) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL1573947 | 0.71 | GAA (0.46) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 | |
| SCHEMBL1574501 | 0.71 | GAA (0.46) | ALDH1A1KDM4ERAB9AHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968719-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| EP-1713779-B1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-7528155-B2 | Indazole derivatives as inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215824-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE SENSITIVE LIPASE | LIPE, PNLIP, CEL | ALDH1A1 479/4885KDM4E 3396/4885RAB9A 3348/4885 |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | ALDH1A1 479/4885KDM4E 3396/4885RAB9A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.